Aleksia Therapeutics
Aleksia Therapeutics is a pre-revenue, privately-held biotech founded in 2022 in Golden, Colorado, combining chemistry and biology expertise to develop cancer therapeutics for patients with hard-to-drug genetic alterations.
- Company typePrivate
- Founded2022
- HeadquartersGolden, United States
- Headcount1–10
- GTM typeB2B
- OfferingServices
What Aleksia Therapeutics does
Aleksia Therapeutics is a privately-held biotechnology research company founded in 2022 and headquartered in Golden, Colorado. The company focuses on developing cancer therapeutics for patients whose cancers are driven by genetic alterations that fall beyond the reach of conventional therapies. It positions itself on combining chemistry and biology expertise to address hard-to-drug targets in oncology, with the stated aim of improving outcomes for patients in this underserved population. Co-founder Michael Kim is the named leadership figure.
The company is at an early research and development stage. No commercial products, named therapeutic candidates, pipeline assets, or licensing deals are disclosed in the available sources. The website functions as a minimal informational presence with a contact email ([email protected]) and an explicit invitation for partnership inquiries. No patents, trademarks, regulatory actions, or published research are referenced. Headcount is reported at 11-50 employees, though no individual team members beyond the co-founder are identified.
Aleksia's business model is not yet defined by commercial revenue. It is pre-revenue with no publicly disclosed pricing, funding rounds, investors, or monetization mechanism. The company appears to be operating through direct outreach to potential collaborators in the oncology/biotech ecosystem, using its website as the primary engagement channel. The copyright notice on the website extends to 2026, indicating ongoing operations.
Aleksia Therapeutics firmographics
Firmographics- Name
- Aleksia Therapeutics
- Legal name
- Aleksia Therapeutics
- Website
- https://aleksiatx.com
- Company type
- Private
- Founded year
- 2022
- Operating status
- Operating
- Headcount range
- 1–10 employees
- Short description
- Aleksia Therapeutics is a pre-revenue, privately-held biotech founded in 2022 in Golden, Colorado, combining chemistry and biology expertise to develop cancer therapeutics for patients with hard-to-drug genetic alterations.
- Ownership category
- akta.pro rank
Aleksia Therapeutics industry classification
Industry- Product category
- Oncology Therapeutics
- NAICS
- Research and Development in Biotechnology (except Nanobiotechnology) (541714)
- SIC
- Pharmaceutical Preparations (2834), Services-Commercial Physical & Biological Research (8731)
- akta.pro primary industry
- Medical Oncology (HLAKAFAB)
- akta.pro secondary industry
- Genetic & Genomic Rare Disease Therapeutics (HLAIAIAA)
Keywords
Where Aleksia Therapeutics is headquartered
LocationHeadquarters
- HQ city
- Golden
- HQ country
- United States
- HQ region
- North America
Markets served
Aleksia Therapeutics business model
Business model- GTM type
- B2B
- Offering type
- Services
- Cost components
- Personnel, Technology or R&D, Operations
Marketing channels1 record
Aleksia Therapeutics product offering
Product offeringCore offering
Aleksia Therapeutics is a pre-revenue biotechnology research company developing cancer therapeutics for patients whose cancers are driven by genetic alterations beyond the reach of conventional therapies. The company combines chemistry and biology expertise to tackle hard-to-drug targets in oncology, with the goal of impacting outcomes for patients with cancer. No named therapeutic candidates or commercial products have been launched; engagement is currently via direct partnership inquiries.
Product overview
Aleksia Therapeutics is a biotechnology company focused on developing cancer therapeutics for patients with genetic alterations that are beyond the reach of conventional therapies. The company combines chemistry and biology expertise to tackle hard-to-drug targets, with the goal of impacting outcomes for patients with cancer. The company does not appear to have launched any commercial products or named therapeutic candidates on its website; it is in the research/development stage and invites partnership inquiries.
Differentiator
Problem solved
Functional benefit
Companies that use Aleksia Therapeutics
Customer profileSegments1 record
Ideal customer profiles1 record
Aleksia Therapeutics technology and API
TechnologyTechnology focussed No
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Aleksia Therapeutics partnerships and signals
Strategic signalRecent moves3 records
Expansion highlights3 records
Aleksia Therapeutics competitors and assessment
Company assessmentDirect peers
- Kymera Therapeutics: Kymera Therapeutics develops targeted protein degraders against oncology and immunology targets previously considered undruggable. Overlaps with Aleksia's hard-to-drug oncology targeting.
- Tango Therapeutics: Tango Therapeutics is a precision oncology biotech developing medicines against cancer targets defined by genetic alterations, including hard-to-drug synthetic-lethal targets. It is the most direct comp to Aleksia's gene-alteration oncology focus.
- Relay Therapeutics: Relay Therapeutics is a clinical-stage precision oncology company using motion-based drug design against previously undruggable cancer targets. Comparable to Aleksia's hard-to-drug-target discovery focus.
- Foghorn Therapeutics: Foghorn Therapeutics develops medicines targeting the chromatin regulatory system in cancer, an undruggable class of oncology targets. Highly comparable to Aleksia's hard-to-drug-target thesis.
- Black Diamond Therapeutics: Black Diamond Therapeutics is a precision oncology company designing small molecules against genetically defined cancer targets. Its focus on genetic alterations in cancer parallels Aleksia's positioning.
- Revolution Medicines: Revolution Medicines develops targeted inhibitors against hard-to-drug oncology targets, particularly RAS-driven cancers. Its hard-to-drug-target positioning closely mirrors Aleksia's stated focus.
- Arvinas: Arvinas pioneered targeted protein degradation as an approach to previously undruggable disease targets in oncology. Comparable as a chemistry-based platform attacking previously inaccessible oncology biology.
Broad incumbents
- Schrödinger: Schrödinger operates a physics-based computational platform for drug discovery, including its own oncology pipeline. Broad incumbent in chemistry-driven drug discovery applicable to hard-to-drug targets.
- Recursion Pharmaceuticals: Recursion is a tech-enabled drug discovery company applying AI and high-throughput biology to oncology and other disease targets. Comparable as a platform-biotech leveraging novel discovery engines against hard targets.
Emerging players
- Erasca: Erasca is a precision oncology company developing therapies targeting the RAS/MAPK pathway. Adjacent emerging oncology player pursuing genetically driven cancer subsets.
Market position
Strengths3 records
Weaknesses3 records
Competitive moat2 records
Key risks5 records
Key highlights4 records
Customer concentration
Aleksia Therapeutics social profiles
Digital presenceAleksia Therapeutics financial estimates
Financial estimateRevenue estimate
Valuation estimate
Aleksia Therapeutics leadership team
Management profileNumber of profiles
Profiles1 record
Aleksia Therapeutics funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Aleksia Therapeutics M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Aleksia Therapeutics
What does Aleksia Therapeutics do?
Aleksia Therapeutics is a pre-revenue biotechnology research company developing cancer therapeutics for patients whose cancers are driven by genetic alterations beyond the reach of conventional therapies. The company combines chemistry and biology expertise to tackle hard-to-drug targets in oncology, with the goal of impacting outcomes for patients with cancer. No named therapeutic candidates or commercial products have been launched; engagement is currently via direct partnership inquiries.
When was Aleksia Therapeutics founded?
Aleksia Therapeutics was founded in 2022. It employs 1 to 10 people.
Where is Aleksia Therapeutics based?
Aleksia Therapeutics is headquartered in Golden, United States, in the North America region.
Who are Aleksia Therapeutics's main competitors?
Direct peers on record are Kymera Therapeutics, Tango Therapeutics, Relay Therapeutics, Foghorn Therapeutics, Black Diamond Therapeutics, Revolution Medicines and Arvinas. Broad incumbents are Schrödinger and Recursion Pharmaceuticals. Erasca is listed as an emerging player.
Does Aleksia Therapeutics have an API?
No public API is recorded for Aleksia Therapeutics.
What industry is Aleksia Therapeutics in?
Aleksia Therapeutics's product category is Oncology Therapeutics. Its primary akta.pro industry code is HLAKAFAB, Medical Oncology, with a secondary code of HLAIAIAA, Genetic & Genomic Rare Disease Therapeutics. Its NAICS code is 541714 and its SIC code is 2834.